Connect your AI

Veradermics MANE Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Natera, Inc.NTRA

$58.86M-45.6%

CognexCGNX

$44.29M+1,812%

Halozyme TherapeuticsHALO

$4.15M+15.6%

RB GlobalRBA

$0—

PopularBPOP

——

SSN

SSNTSSNT

——

Other financials

Income statement

Operating income-$29.9M-131%

Net income-$27.2M-120%

EPS (diluted)-$1.32+93.3%

Balance sheet

Cash & equivalents$168.4M+419%

Total debt$4.0K—

Total equity$390.6M+744%

Total assets$397.4M—

Cash flow

Operating cash flow-$21.2M-59.0%

CapEx--100%

Free cash flow-$21.2M-58.7%

Valuation

Market cap$3.92B—

Returns & leverage

Return on equity-28.7%—

Current ratio59.1×—

Where this comes from

Reported directly by Veradermics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: Veradermics ’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Veradermics 's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Veradermics 's stock issuance proceeds?: Veradermics (MANE) reported stock issuance proceeds of $11K in Q1 2026.
What does stock issuance proceeds mean?: Cash received from selling company shares.
How do you interpret stock issuance proceeds?: Higher values indicate successful capital raising, providing liquidity for operations.
How does stock issuance proceeds compare across companies?: A primary funding mechanism for pre-revenue biopharma companies.